SCHEMBL2820716

SCHEMBL2820716

[c]1cc(-c2cccnc2)[nH]n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 7/20 0.55
CYP2E1 P05181 2/20 0.55
CYP2B6 P20813 2/20 0.55
ALDH1A1 P00352 4/20 0.50
CYP3A4 P08684 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
CYP19A1 P11511 1/20 0.44
NISCH Q9Y2I1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69802 0.78 SCN4A (0.45) ALDH1A1CYP3A4HSD17B10KDM4EMAPT
SCHEMBL4044619 0.77 MKNK1 (0.41) CYP3A4CYP19A1IDO1
SCHEMBL5092536 0.76 PDPK1 (0.48) LMNATP53MAPTNISCHNPY5R
SCHEMBL6381205 0.73 CYP2A6 (0.54) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4
SCHEMBL4047215 0.73 CYP1A2 (0.40) ALDH1A1CYP3A4CYP1A2HSD17B10KDM4E
SCHEMBL29597274 0.71 CYP2A6 (1.00) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4
SCHEMBL13425468 0.71 CYP2A6 (1.00) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4
SCHEMBL30473120 0.70 CYP2A6 (1.00) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4
SCHEMBL29419014 0.70 CYP2A6 (1.00) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4
SCHEMBL120088 0.70 CYP2A6 (1.00) CYP2A6CYP2E1CYP2B6ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010075356-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-07-01 WO disclosed
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-06-24 US disclosed
US-7393873-B2 Arylsulfonamide derivatives MERCK & CO., INC. (US) 2008-07-01 US disclosed
US-20060142612-A1 Arylsulfonamide derivatives MERCK SHARP & DOHME CORP. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160323-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 CYP2A6 1654/4885CYP2E1 1363/4885CYP2B6 2144/4885
US-20060142612-A1 Arylsulfonamide derivatives BDKRB1, BDKRB2, LTB4R2 CYP2A6 759/4885CYP2E1 815/4885CYP2B6 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.